Ranolazine is a prescription medication used to treat chronic angina, the recurring chest pain that happens when your heart muscle doesn’t get enough oxygen-rich blood. It’s not a rescue medication for sudden chest pain episodes. Instead, it works as a long-term treatment to reduce how often angina attacks occur and to help you exercise longer without triggering symptoms. The FDA approved it in 2006 under the brand name Ranexa.
How Ranolazine Treats Chronic Angina
Most angina medications work by either reducing how hard the heart pumps or by widening blood vessels to improve blood flow. Ranolazine takes a different approach entirely. It targets a problem at the cellular level inside heart muscle cells.
In a struggling heart, certain sodium channels in the muscle cells stay open longer than they should. This lets too much sodium flood into the cells, which in turn causes a buildup of calcium. That excess calcium makes the heart muscle stiffen during the phase when it should be relaxing between beats. A stiff, poorly relaxing heart compresses its own blood vessels and starves itself of oxygen, which is what triggers the pain of angina.
Ranolazine blocks those overactive sodium channels, reducing the sodium and calcium buildup. The heart muscle relaxes more effectively between beats, blood flows more freely through its internal vessels, and oxygen delivery improves. Because it works this way rather than lowering heart rate or blood pressure, it can be added on top of other heart medications without compounding their side effects.
Who Typically Takes It
Ranolazine is generally prescribed for people whose angina isn’t adequately controlled by first-line medications like beta-blockers, calcium channel blockers, or nitrates. The FDA label specifically notes that it has been evaluated in patients who remained symptomatic despite treatment with maximum doses of another antianginal drug. It can be used alongside all of these, as well as with blood thinners, cholesterol-lowering drugs, and blood pressure medications.
It is not appropriate for everyone. People with liver cirrhosis cannot take ranolazine because the liver is the primary organ responsible for breaking it down. It’s also contraindicated if you take certain medications that strongly affect the same liver enzyme pathway (CYP3A), since these can either dangerously raise or lower ranolazine levels in your blood.
What the Clinical Trials Showed
The key trial supporting ranolazine’s approval, known as CARISA, enrolled patients with severe chronic angina who were already on another antianginal medication. Participants who added ranolazine were able to exercise about 24 seconds longer on a treadmill test compared to those who added a placebo. That may sound modest, but for someone whose daily activities are limited by chest pain, even small improvements in exercise tolerance can translate into meaningful quality-of-life gains, like walking to the mailbox or climbing a flight of stairs without stopping.
The trial also showed that ranolazine reduced the frequency of weekly angina episodes, meaning fewer days interrupted by chest pain and less reliance on fast-acting nitroglycerin for relief.
Dosing and What to Expect
Ranolazine comes as an extended-release tablet, meaning it dissolves slowly and keeps a steady level of medication in your system throughout the day. The typical starting dose is 500 mg taken twice daily. If your symptoms aren’t adequately controlled, your prescriber may increase it to 1,000 mg twice daily, which is the maximum recommended dose.
The tablets need to be swallowed whole. Crushing or chewing them would release the full dose at once rather than gradually, which could cause problems. In Europe, the approved dosing is slightly different: prescribers start at 375 mg twice daily and can go up to 750 mg twice daily, with dose increases recommended after two to four weeks.
Important Drug Interactions
Ranolazine interacts with a notable number of other medications, which is one reason it requires careful prescribing. If you take diltiazem or verapamil (common calcium channel blockers), your ranolazine dose typically needs to be capped at 500 mg twice daily because these drugs slow ranolazine’s breakdown and raise its blood levels.
Cholesterol medications are another consideration. If you take simvastatin, the dose generally needs to stay at 20 mg or below while on ranolazine, because ranolazine increases simvastatin exposure and raises the risk of muscle-related side effects. Similar adjustments may apply to lovastatin. Digoxin levels also rise when combined with ranolazine, so monitoring and dose changes are often needed. Even certain antidepressants and antipsychotics can be affected, potentially requiring lower doses.
Potential Role in Atrial Fibrillation
Beyond its approved use for angina, ranolazine has attracted interest as a possible treatment for atrial fibrillation, a common heart rhythm disorder. The same sodium channel mechanism that helps with angina also appears to stabilize the electrical activity of the upper chambers of the heart.
In laboratory studies using heart tissue from dogs with heart failure, a clinically relevant concentration of ranolazine suppressed the triggering of atrial fibrillation in 7 out of 10 tissue preparations. In the remaining three, it still reduced how long and how frequently the arrhythmia occurred. Importantly, it did not promote dangerous rhythm problems in the lower chambers of the heart, which is a concern with many antiarrhythmic drugs. Researchers at the American Heart Association have suggested it could serve as an alternative to existing rhythm-control drugs in heart failure patients, though dedicated clinical trials in humans are still needed before this becomes a standard recommendation.
Unexpected Effects on Blood Sugar
One of the more surprising findings about ranolazine came from a large trial of patients hospitalized for a type of heart attack. Researchers noticed that patients with diabetes who took ranolazine saw meaningful drops in their blood sugar marker, HbA1c. For diabetic patients whose HbA1c was between 8% and 10% at the start (indicating poor blood sugar control), ranolazine lowered HbA1c by 1.2 percentage points overall, with 0.59 percentage points of that reduction attributable to ranolazine rather than other factors. Even patients with better-controlled diabetes (HbA1c between 6% and 8%) saw a placebo-corrected reduction of 0.28 percentage points.
These reductions are clinically meaningful. For context, many dedicated diabetes medications aim for HbA1c reductions in this same range. Ranolazine is not prescribed as a diabetes treatment, but this effect is a notable bonus for the many angina patients who also have diabetes. The mechanism likely relates to ranolazine’s effects on sodium channels in the pancreas, which influence insulin release, though this is still being studied.
Common Side Effects
The most frequently reported side effects are dizziness, headache, constipation, and nausea. These tend to be dose-related, meaning they’re more common at the 1,000 mg twice-daily dose than at the lower starting dose. Ranolazine does cause a small prolongation of the QT interval on an electrocardiogram, which is a measure of the heart’s electrical recovery time. For this reason, prescribers monitor for this effect, particularly in patients taking other medications that also affect the QT interval. Despite this signal on heart tracings, clinical trials have not shown an increase in dangerous heart rhythm events with ranolazine use.